Recommendations for the prevention and correction of thrombotic complications in COVID-19

Abstract

The new coronavirus infection caused by the SARS-CoV-2 virus (COVID-19) is characterized by a high frequency of thrombotic complications varying from venous or, more rarely, arterial thrombosis to the development of disseminated intravascular coagulation (DIC) and/or diffuse pulmonary vascular microthrombosis, which aggravates the disease and becomes one of the leading causes of deaths. Timely and personalized anticoagulant thromboprophylaxis with low-molecular-weight heparins may prevent a severe course of the disease and improve outcomes. This applies to outpatients, hospitalized patients and patients in the early post hospital period. In the future, to develop comprehensive and evidence-based guidelines on the management of patients with COVID-19, it is necessary to conduct comprehensive systematic studies and comparative clinical trials of prophylaxis and treatment of hemostatic disorders in patients with COVID-19.

Keywords

coronavirus disease 2019 / SARS-CoV-2 / thrombosis / hemostatic disorders / anticoagulant therapy

References

[1] Christopher D.B., Hunter B.M., Michael B.Y., Ernest E.M. ISTH interim guidance on recognition and ma­nagement of coagulopathy in COVID-19: a comment. 2020 Apr 17. DOI: 10.1111/jth.14860.

[2] Yang X., Yu Y., Xu J. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet. Respir. Med. 2020; 8: 475–481. DOI: 10.1016/S2213-2600(20)30079-5.

[3] Han H., Yang L., Liu R. et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin. Chem. Lab. Med. 2020 Mar 16. DOI: 10.1515/cclm-2020-0188.

[4] Lillicrap D. Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia. J. Thromb. Haemost. 2020; 18: 786–787. DOI: 10.1111/jth.14781.

[5] Engelmann B., Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat. Rev. Immunol. 2013; 13: 34–45. DOI: 10.1038/nri3345.

[6] Delabranche X., Helms J., Meziani F. Immunohaemostasis: a new view on haemostasis during sepsis. Ann. Intensive Care. 2017; 7: 117. DOI: 10.1186/s13613-017-0339-5.

[7] Jackson S.P., Darbousset R., Schoenwaelder S.M. Thromboinflammation: challenges of therapeutically targe­ting coagulation and other host defense mechanisms. Blood. 2019; 133: 906–918. DOI: 10.1182/blood-2018-11-882993.

[8] Giani M., Seminati D., Lucchini A. et al. Exuberant plasmocytosis in bronchoalveolar lavage specimen of the first patient requiring extracorporeal membrane oxygena­tion for SARS-CoV-2 in Europe. J. Thorac. Oncol. 2020; 15 (5): e65–e66. DOI: 10.1016/j.jtho.2020.03.008.

[9] Whyte C.S., Morrow G.B., Mitchell J.L. et al. Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID‐19. J. Thromb. Haemost. 2020 Apr 23. DOI: 10.1111/jth.14872.

[10] Temporary guidelines “Prevention, dia­gnosis and treatment of the new coronavirus infection (COVID-19)”. Ministry of Health of the Russian Fede­ration. Version 6. 28.04.2020. 164 р. https://static-1.rosminzdrav.ru/system/attachments/attaches/000/050/116/original/28042020_%D0%9CR_COVID-19_v6.pdf (access date: 14.05.2020). (In Russ.)

[11] Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)». Министерство здравоохранения РФ. Версия 6 (28.04.2020). 164 с. https://static-1.rosminzdrav.ru/system/attachments/attaches/000/050/116/original/28042020_%D0%9CR_COVID-19_v6.pdf (дата обращения: 14.05.2020).

RIGHTS & PERMISSIONS

Safiullina S.I., Litvinov R.I.